Each winter, thousands of New Zealand infants are hospitalised with a virus that much of the developed world has already learned to prevent. Respiratory syncytial virus — RSV — strikes hardest among Māori and Pacific babies, whose families carry a disproportionate share of a burden that is both predictable and, by now, well within reach of prevention. While Australia, the United Kingdom, the United States, and much of Europe have woven RSV immunisation into their national programmes, New Zealand remains in deliberation, held back not by insufficient evidence but by insufficient urgency.
NZ lags behind on RSV infant protection despite proven 90% hospitalization reduction
Approximately 1,800-2,000 children under five are hospitalised annually with RSV in New Zealand, with Māori and Pacific infants experiencing disproportionate disease burden.
Every winter, RSV creates a surge of preventable illness
Mark
Why has New Zealand been slower than other countries to adopt RSV immunisation?
Mimi
The briefing doesn't say explicitly, but the implication is clear—it's not about the science. The evidence is there. It's about process. Dobinson specifically mentions the vaccine assessment system as a potential bottleneck. Sometimes the machinery of approval just moves slower than the evidence warrants.
Mark
What makes RSV different from other childhood illnesses we already vaccinate against?
Mimi
RSV is seasonal and predictable, which is almost worse in a way. We know it's coming every winter. We know which babies will suffer most. And now we have tools that work. That predictability makes the delay harder to justify.
Mark
The equity angle—is that the main reason this matters, or is it secondary?
Mimi
It's not secondary. Māori and Pacific infants are hit disproportionately hard, and that's not incidental. It's central to why this matters. But even for all infants, RSV hospitalisation is disruptive and sometimes dangerous. The equity piece just sharpens the urgency.
Mark
If these vaccines are 70-90% effective, does that mean some babies still get severely ill?
Mimi
Yes. Nothing is 100 percent. But preventing seven or nine out of ten severe cases is extraordinary. That's the difference between a manageable winter and a crisis winter in paediatric wards.
Mark
What happens if New Zealand keeps waiting?
Mimi
More babies get hospitalised than need to. More families are disrupted. More pressure on hospitals when they're already stretched. And the gap between us and comparable countries just widens. At some point, the delay itself becomes a choice.
El Pulso
- Between 1,800 and 2,000 New Zealand children under five are hospitalised with RSV every winter — half of them babies under six months — making this one of the most consistent and foreseeable crises in the country's paediatric wards.
- Māori and Pacific infants bear a disproportionate burden of severe infection, meaning the cost of inaction is not distributed evenly but falls heaviest on communities already navigating compounding disadvantage.
- Long-acting monoclonal antibodies and maternal vaccination have demonstrated 70–90% reductions in RSV hospitalisations internationally, with comparable nations already running these programmes at scale.
- New Zealand's health authorities have not yet moved RSV immunisation onto the National Immunisation Programme, leaving a proven intervention waiting while children continue to be admitted each winter.
- Paediatric specialists are now calling not for more research but for faster decisions — urging a review of vaccine assessment timelines to prevent bureaucratic delay from becoming its own form of harm.
Each winter, thousands of New Zealand infants are hospitalised with a virus that much of the developed world has already learned to prevent. Respiratory syncytial virus — RSV — strikes hardest among Māori and Pacific babies, whose families carry a disproportionate share of a burden that is both predictable and, by now, well within reach of prevention. While Australia, the United Kingdom, the United States, and much of Europe have woven RSV immunisation into their national programmes, New Zealand remains in deliberation, held back not by insufficient evidence but by insufficient urgency.
Every winter, New Zealand's paediatric wards fill with infants struggling to breathe. RSV hospitalises between 1,800 and 2,000 children under five each year — roughly half of them babies under six months old — and it strikes hardest among Māori and Pacific families, in crowded homes, in communities where poverty and poor housing concentrate the risk. The illness is predictable. The tools to prevent it now exist. What is missing is the decision to use them.
Australia, the United Kingdom, the United States, Chile, and most of Europe have already moved. They are using two strategies: long-acting monoclonal antibodies given to newborns, and maternal vaccination administered during pregnancy. Real-world data shows these interventions reduce RSV-related hospital admissions by 70 to 90 percent. Maternal vaccination protects infants up to six months old with roughly 70 percent effectiveness. These are not incremental improvements — they are transformative reductions in childhood illness that also ease pressure on hospital systems at their most stretched.
Dr Hazel Dobinson, a paediatric infectious disease specialist and lead author of a new briefing from the Public Health Communication Centre, puts the situation plainly: the science is settled, the international evidence is clear, and what New Zealand lacks is not knowledge but action. Every preventable admission represents a family disrupted, a parent unable to work, a child whose early respiratory illness may leave lasting effects.
The equity dimension sharpens the urgency. Māori and Pacific infants are disproportionately affected by severe RSV — a pattern rooted in broader inequities around housing, income, and healthcare access. An immunisation programme would not resolve those inequities, but it would interrupt one concrete pathway through which they become serious illness.
Dobinson and her colleagues are not calling for caution or further study. They are calling for speed — urging New Zealand to review its vaccine assessment process and implement RSV immunisation through the National Immunisation Programme without further delay. The question is no longer whether these interventions work. The question is how much longer New Zealand will wait.
Every winter, New Zealand's emergency departments and paediatric wards fill with infants struggling to breathe. Respiratory syncytial virus—RSV—sends between 1,800 and 2,000 children under five to hospital each year, and about half of those admissions are babies under six months old. The virus hits hardest in the families least able to absorb the shock: Māori and Pacific infants, children in crowded homes, kids growing up in neighbourhoods where poverty clusters. It is predictable. It is preventable. And New Zealand is not preventing it.
Across the Tasman and throughout much of the developed world, the conversation has moved past whether to protect infants from RSV and settled into the practical work of how. Australia, the United Kingdom, the United States, Chile, and most of Europe have already woven RSV immunisation into their national vaccination schedules. They are using two proven strategies: long-acting monoclonal antibodies administered to newborns, and maternal vaccination given during pregnancy. The evidence is unambiguous. Real-world data shows the monoclonal antibodies cut RSV-related hospital admissions by 70 to 90 percent. Maternal vaccination prevents severe infection in infants up to six months old with roughly 70 percent effectiveness. These are not marginal gains. These are transformative reductions in childhood illness.
Dr Hazel Dobinson, a paediatric infectious disease specialist and lead author of a new briefing from the Public Health Communication Centre, frames the gap plainly. New Zealand has the tools. The science is settled. What is missing is the decision to act. "We now have highly effective immunisation options that can prevent many severe RSV infections in infancy," Dobinson says. "International experience shows these programmes reduce hospital admissions and can make a real difference for babies, whānau and health services." The briefing she authored lays out the case with clinical precision: every winter, RSV creates a surge of preventable illness that ripples through families and strains hospital systems at their most fragile moment. Fewer babies in intensive care means more capacity for other emergencies. It means parents not missing work. It means children not scarred by early severe respiratory illness.
The equity dimension cuts deeper still. Māori and Pacific infants are disproportionately affected by severe RSV, a pattern that reflects broader inequities in housing, income, and access to healthcare. An RSV immunisation programme would not erase those inequities, but it would interrupt one concrete pathway through which they become illness. A baby protected is a baby whose whānau is not disrupted, whose community does not absorb another preventable loss.
Dobinson and her colleagues are not calling for caution or further study. They are calling for speed. "The RSV immunisation is a high-impact and economically efficient intervention that justifies rapid approval and implementation through the National Immunisation Programme," she says. They recommend that New Zealand review its vaccine assessment process—not to lower standards, but to ensure that proven, effective interventions do not languish in bureaucratic delay while children continue to be hospitalised. The question is no longer whether RSV immunisation works. The question is why New Zealand is still asking.
Citas Notables
We now have highly effective immunisation options that can prevent many severe RSV infections in infancy. International experience shows these programmes reduce hospital admissions and can make a real difference for babies, whānau and health services.— Dr Hazel Dobinson, Paediatric Infectious Disease Specialist
The RSV immunisation is a high-impact and economically efficient intervention that justifies rapid approval and implementation through the National Immunisation Programme.— Dr Hazel Dobinson
Quieres la nota completa?
Lee el original en Public Health Communication Centre ↗
Health & Medicine